Compare HCTI & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCTI | VTGN |
|---|---|---|
| Founded | 2020 | 1998 |
| Country | United States | United States |
| Employees | 58 | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 10.8M |
| IPO Year | 2021 | 2014 |
| Metric | HCTI | VTGN |
|---|---|---|
| Price | $0.66 | $0.29 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | 2.6M | ★ 18.6M |
| Earning Date | 04-16-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,891,000.00 | N/A |
| Revenue This Year | $79.33 | $124.49 |
| Revenue Next Year | $20.00 | $353.99 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.77 | N/A |
| 52 Week Low | $0.14 | $0.20 |
| 52 Week High | $9.97 | $5.14 |
| Indicator | HCTI | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.66 | 56.20 |
| Support Level | $0.14 | $0.22 |
| Resistance Level | $1.01 | $0.32 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 1.24 | 21.15 |
Healthcare Triangle Inc is a healthcare information technology company focused on advancing industry-transforming solutions in the sectors of cloud services, data science, and professional and managed services for the healthcare and life sciences industry. The company reinforces healthcare progress through technology and extensive industry know-how. HTI supports healthcare providers and payors, hospitals, and Pharma Life Sciences organizations in their efforts to improve health outcomes by enabling the adoption of new technologies, data enlightenment, business agility, and accelerated response to immediate business needs and competitive threats. It provides services under three operating segments: Software Services, Managed Services, and Support and Corporate & others.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.